Hemispherx Achieves High Ranking in Sensitivity Testing Against MERS/SARS Coronaviruses Compared to Other Drugs
July 22, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that a new publication abstract in Infectious Disorder Drug Targets (2014 Jul 13. [Epub ahead of print])...
Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS)
June 16, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that a new publication (June 2, 2014) in the Formulary Journal...
Hemispherx Announces That the University of Texas Medical Branch Confirms Activity of Alferon(R) N Against MERS (Middle East Respiratory Syndrome) Virus
June 03, 2014 13:06 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it has confirmed that one of its advanced stage biological products, Alferon® N, inhibits...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2014
May 09, 2014 16:15 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 9, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2014. The net loss (including non-cash effects)...
Alferon(R) N Effective Against MERS (Middle East Respiratory Syndrome) Virus In-Vitro
May 05, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 5, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon® N, significantly inhibited the replication...